Genomes and Genes
Summary: Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.
Articles from Journal RESEARCH
Articles from Journal RESEARCH1
Publications217 found, 100 shown here
- A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Ann Neurol 54:403-14. 2003..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results...
- Selective inhibition of striatal fast-spiking interneurons causes dyskinesiasAryn H Gittis
Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA
J Neurosci 31:15727-31. 2011..These results provide direct evidence that hypofunction of striatal FSIs can produce movement abnormalities, and suggest that they may represent a novel therapeutic target for the treatment of hyperkinetic movement disorders...
- Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complicationsKarla Eggert
Department of Neurology, Philipps University of Marburg, Marburg, Germany
Clin Neuropharmacol 31:151-66. 2008..The tolerability, efficacy, and the need for dose adjustment of levodopa infusion were followed-up prospectively. Thereby, we describe clinically relevant details for how to successfully initiate and handle this new treatment strategy...
- Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystoniaJee Young Lee
Department of Neurology, SMG SNU Boramae Medical Center, Seoul, South Korea
Parkinsonism Relat Disord 19:1156-9. 2013To describe the long-term follow-up data of Korean patients with GTP cyclohydrolase (GTPCH) I deficient dopa-responsive dystonia (DRD) with novel mutations and unusual long-lasting dyskinesias.
- PET demonstrates reduced dopamine transporter expression in PD with dyskinesiasA R Troiano
Pacific Parkinson s Research Centre, Vancouver, BC, Canada
Neurology 72:1211-6. 2009b>Dyskinesias are common in Parkinson disease (PD). Prior investigations suggest that dopamine (DA) terminals compensate for abnormal DA transmission...
- Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesiasC G Bachmann
Department of Clinical Neurophysiology, Georg August University, Gottingen, Germany
Eur J Neurol 16:895-901. 2009..We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative ..
- Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trialHideyuki Sawada
Clinical Research Center, Utano National Hospital, Kyoto City, Japan
PLoS ONE 5:e15298. 2010b>Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease...
- Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulataSabrina Boulet
Dynamique des Réseaux Neuronaux, Institut National de la Sante et de la Recherche Medicale, Unité 704, F 38041 Grenoble, France
J Neurosci 26:10768-76. 2006..These new neurochemical data suggest that STN-HFS-induced forelimb dyskinesia is mediated by glutamate, probably via the direct activation of STN axons, shedding light on the mechanisms of STN-HFS in PD...
- Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomesGalit Kleiner-Fisman
Parkinson s Disease Research Education and Clinical Center, Philadelphia VA Hospital, Philadelphia, Pennsylvania 19104, USA
Mov Disord 21:S290-304. 2006..These data provide an estimate of the magnitude of the treatment effects and emphasize the need for controlled and randomized studies...
- Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European studyM Pechevis
Cemka Eval, Bourg la Reine, France
Eur J Neurol 12:956-63. 2005The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias)...
- Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamineWassilios Meissner
Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
Neurobiol Dis 22:586-98. 2006....
- Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challengesRegina Katzenschlager
Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom
Mov Disord 20:151-7. 2005..SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD)...
- Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic reviewS Pappa
Institute of Psychiatry, Division of Psychological Medicine, King s College London, UK
Psychol Med 39:1065-76. 2009..Their presence has been documented extensively in chronic schizophrenia but not at the time of illness onset...
- Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian ratsKatherine E Soderstrom
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Eur J Neurosci 31:478-90. 2010..However, analyses of vibrissae-induced forelimb use, levodopa-induced dyskinesias and graft-induced dyskinesias showed significant improvement in rats with dopamine grafts associated with ..
- RAD51 haploinsufficiency causes congenital mirror movements in humansChristel Depienne
INSERM, U CRICM, Hopital Pitie Salpetriere, Paris, France
Am J Hum Genet 90:301-7. 2012..These findings open a new field of investigation for researchers attempting to unravel the molecular pathways underlying bimanual motor control in humans...
- Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson diseaseUrszula Adamiak
Departments of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
Clin Neuropharmacol 33:135-41. 2010..pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations.
- Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-upR G McCreadie
Crichton Royal Hospital, Dumfries, UK
Br J Psychiatry 181:135-7. 2002..Spontaneous dyskinesia and parkinsonism have been reported in never-medicated patients with schizophrenia but there has been no previous study of the natural history of these conditions...
- Subthalamic activity during diphasic dyskinesias in Parkinson's diseaseManuel Alegre
Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain
Mov Disord 27:1178-81. 2012Diphasic dyskinesias are a subtype of levodopa-induced dyskinesias that appear typically at the onset and end of levodopa antiparkinsonian action. The pathophysiology of diphasic dyskinesias is not well understood.
- [Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]Can Xing Yuan
Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Zhong Xi Yi Jie He Xue Bao 6:1024-8. 2008..herbal medicine (TCM) for nourishing liver and kidney, clearing meridians and removing toxic substances, on the neurobehavioral manifestations and the activity of the dopamine D2 receptor in rat with levodopa-induced dyskinesias (LID).
- Dyskinesias as a limiting factor in the treatment of Segawa diseaseEduardo Lopez-Laso
Pediatric Neurology Unit, Department of Pediatrics, University Hospital Reina Sofia, Maimónides Institute of Biomedical Research of Córdoba, University of Cordoba, Cordoba, Spain
Pediatr Neurol 46:404-6. 2012..In contrast, the development of levodopa limiting treatment dyskinesias is thought to support the diagnosis of other early-onset dystonia/parkinsonism syndromes...
- Levodopa-induced dyskinesias and their managementFrancesca Del Sorbo
Fondazione IRCCS Istituto Neurologico Carlo Besta, Via G Celoria, 11, 20133, Milano, Italy
J Neurol 255:32-41. 2008This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease...
- Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeysPershia Samadi
Centre de Recherche en Neurosciences, CHUL Sainte Foy, Quebec, Canada
Neuropharmacology 49:165-73. 2005..l-Dopa plus naltrexone the beginning of the therapeutical effect of l-Dopa was accompanied by the appearance of dyskinesias. In this group, the severity of dyskinesias during the third and fourth weeks of treatment was significantly ..
- Dyskinesia after fetal cell transplantation for parkinsonism: a PET studyYilong Ma
Center for Neurosciences, North Shore Long Island Jewish Research Institute and Department of Neurology, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA
Ann Neurol 52:628-34. 2002Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for Parkinson's disease...
- Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiencyPaolo Moretti
Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
J Autism Dev Disord 38:1170-7. 2008..These findings demonstrate that autistic features are salient in CFD and suggest that a subset of children with developmental regression, mental retardation, seizures, dyskinesia, and autism may have CNS folate abnormalities...
- Dyskinesias and associated psychiatric disorders following streptococcal infectionsR C Dale
Neurosciences Unit, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, UK
Arch Dis Child 89:604-10. 2004..Recently, other post-streptococcal movement disorders have been described, including motor tics and dystonia. Associated emotional and behavioural alteration is characteristic...
- Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesiasVincent Paille
INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
Mov Disord 22:533-9. 2007..After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics ..
- Levodopa-induced dyskinesias detection based on the complexity of involuntary movementsMircea I Chelaru
Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
J Neurosci Methods 186:81-9. 2010..The clear difference between the sample entropy-based measures for the non-dyskinetic and dyskinetic patients made possible the automatic, efficient recognition of the dyskinetic condition, based on multi-layer perceptrons...
- Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesiasBelen Ferrer
Fundacion Hospital Carlos Haya, 29010 Malaga, Spain
Eur J Neurosci 18:1607-14. 2003The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment...
- Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal periodVijay A Mittal
Department of Psychology, University of California Los Angeles, Los Angeles, California, USA
Biol Psychiatry 68:93-9. 2010....
- Relevance of the MPTP primate model in the study of dyskinesia priming mechanismsPierre J Blanchet
Department of Stomatology, Faculty of Dental Medicine, University of Montreal, Que, Canada
Parkinsonism Relat Disord 10:297-304. 2004..Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or ..
- Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkeyM Quik
The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
Neuroscience 113:213-20. 2002..in the caudate and putamen have been linked to the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in primate models of Parkinson's disease, although not all investigators have been able to confirm this ..
- Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian populationJimmy Lee
Institute of Mental Health Woodbridge Hospital, Singapore
J Clin Psychopharmacol 28:536-9. 2008..Patients with dyskinetic movements at baseline could have a more treatment refractory course of illness...
- Topography of dyskinesias and torticollis evoked by inhibition of substantia nigra pars reticulataDavid Dybdal
Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA
Mov Disord 28:460-8. 2013..In monkeys, choreiform limb dyskinesias have been described after inhibition of the GPi, but not the SNpr...
- New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptorsFabio Blandini
IRCCS National Neurological Institute C Mondino, Interdepartmental Research Center for Parkinson s Disease, Via Mondino 2, 27100 Pavia, Italy
Expert Opin Investig Drugs 21:153-68. 2012..which is hampered by numerous side effects, including abnormal involuntary movements known as L-DOPA-induced dyskinesias (LIDs)...
- Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's diseaseTomas Bjorklund
Brain Repair and Imaging in Neural Systems, 22184 Lund, Sweden
Brain 133:496-511. 2010..This approach has been shown to be efficient in restoring motor function and reducing established dyskinesias in rats with a partial lesion of the nigrostriatal dopamine projection...
- Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trialChristopher G Goetz
Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:179-86. 2007..Included were PD patients optimized to levodopa and dopaminergic drugs with moderately disabling dyskinesias present greater than or equal to 25% of the waking day...
- Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplantsMarios Politis
Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK
Sci Transl Med 2:38ra46. 2010Troublesome involuntary movements in the absence of dopaminergic medication, so-called off-medication dyskinesias, are a serious adverse effect of fetal neural grafts that hinders the development of cell-based therapies for Parkinson's ..
- Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratioMarios Politis
Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
Mov Disord 26:1997-2003. 2011Graft-induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease...
- Stimulation of subthalamic fibre tracts reduces dyskinesias in STN-DBSJ Herzog
Department of Neurology, Neurozentrum, Christian Albrechts Universitat Kiel, Kiel, Germany
Mov Disord 22:679-84. 2007..of patients with subthalamic deep brain stimulation (STN-DBS) is complicated by pharmacologically intractable dyskinesias. Here we report that in three of these patients additional stimulation of a proximal contact located within the ..
- Graft-induced dyskinesias in Parkinson's disease: what is it all about?Roger A Barker
Brain Repair Centre and Department of Neurology, University of Cambridge, Cambridge CB2 0PY, UK
Cell Stem Cell 7:148-9. 2010..with grafts of fetal ventral mesencephalic tissue has shown some success, but can result in graft-induced dyskinesias (GIDs). Recently in Science Translational Medicine, Politis et al...
- Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?Marios Politis
Centre for Neuroscience, Medical Research Council, Hammersmith Hospital, Imperial College London, UK
BMC Med 8:80. 2010..uncontrolled movements in the absence of dopaminergic medication, so-called off-phase, graft-induced dyskinesias. Notwithstanding the several mechanisms having been proposed, the pathogenesis of this type of dyskinesias ..
- Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspectivePeter Hagell
Department of Nursing, Lund University, P O Box 157, SE 221 00 Lund, Sweden
Brain Res Bull 68:4-15. 2005Both increased and decreased dyskinesias have been reported from open label clinical trials of transplantation of human embryonic dopamine rich tissue in Parkinson's disease patients...
- Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysisC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
Mov Disord 24:336-43. 2009The objective of this study is to assess dyskinesias in 34 Parkinson's disease patients randomized to receive bilateral fetal nigral transplantation with 4 donors per side (12), 1 donor per side (11), or placebo (11)...
- Inversion of dopamine responses in striatal medium spiny neurons and involuntary movementsLi Liang
Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia 30322, USA
J Neurosci 28:7537-47. 2008..These findings point to the fundamental role of dopamine-mediated balance of striatal outputs for normal movement...
- Unawareness of dyskinesias in Parkinson's and Huntington's diseasesC Vitale
Department of Neurological Sciences, University Federico II, Naples, Italy
Neurol Sci 22:105-6. 2001We performed a clinical study to evaluate the unawareness of dyskinesias in patients affected by Parkinson's disease (PD) and Huntington's disease (HD)...
- A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's diseaseJaime Kulisevsky
Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Spain
Clin Neuropharmacol 25:25-31. 2002..of the effect of levodopa in all Unified Parkinson's Disease Rating Scale variables considered, including dyskinesias, maximal levodopa-induced improvement and the duration of the effect of levodopa did not differ significantly ..
- Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeysAlbert Hsu
The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
J Pharmacol Exp Ther 311:770-7. 2004..Parkinson's disease, continued treatment may result in excessive involuntary movements known as L-dopa-induced dyskinesias (LIDs)...
- Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesiasR C Dodel
Department of Neurology, Philipps University Marburg, Germany
Pharmacoeconomics 19:1013-38. 2001..as changes between akinetic and mobile phases (motor fluctuations) or as abnormal involuntary movements (dyskinesias)...
- ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian miceNancy Pavon
Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
Biol Psychiatry 59:64-74. 2006..A major complication of this therapy, however, is the appearance of the abnormal involuntary movements known as dyskinesias. We have developed a model of L-DOPA-induced dyskinesias in mice that reproduces the main clinical features of ..
- Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's diseaseManolo Carta
Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
Mov Disord 25:S174-9. 2010..This mechanism may also play a role in the development of graft-induced dyskinesias in patients that receive fetal neuron transplants, possibly due to the inclusion of serotonin neurons in the ..
- L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian miceEmanuela Santini
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
J Neurochem 108:621-33. 2009..Our results demonstrate that in the dopamine-depleted striatum, L-DOPA activates ERK signaling specifically in striatonigral MSNs. This regulation may result in ERK-dependent changes in striatal plasticity leading to dyskinesia...
- Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseB Henry
Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester, Stopford Building, Manchester, M13 9PT, United Kingdom
Exp Neurol 171:139-46. 2001..These data suggest that specific mu- or delta-opioid receptor antagonists might be applicable clinically in the treatment of levodopa-induced dyskinesia in Parkinson's disease...
- Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyR Pahwa
University of Kansas Medical Center, Kansas City, USA
Neurology 66:983-95. 2006..5. Preoperative response to levodopa predicts better outcome after DBS of the STN (Level B)...
- Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesiasG Foffani
Dipartimento di Scienze Neurologiche, Clinica Neurologica, Padiglione Ponti, Ospedale Maggiore Policlinico, Via F Sforza 35, Milano, 20122 Italy
J Neurol Neurosurg Psychiatry 76:426-8. 2005The aim of this work was to study the role of subthalamo-pallidal synchronisation in the pathophysiology of dyskinesias. We recorded local field potentials (LFPs) in a patient with Parkinson's disease and left surgery induced dyskinesias ..
- Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeysPershia Samadi
Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Quebec CHUQ, Ste Foy, Quebec, Canada
Ann Neurol 59:282-8. 2006..study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.
- Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal gangliaAgnes Nadjar
Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux, France
J Neurosci 26:8653-61. 2006..Striatofugal pathways are not as segregated in the primate as previously considered...
- High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesiasAlexander Storch
Department of Neurology, University of Ulm, Ulm, Germany
Parkinsonism Relat Disord 11:393-8. 2005..3+/-3.8 to 1.7+/-0.9 h per day (p < 0.001) measured by patients' diaries. Dyskinesias, present for 5.0+/-3.3 h per day at baseline, were reduced to 1.4+/-0.8 h per day (p < 0...
- Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseP J Hallett
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA
Neuropharmacology 48:503-16. 2005The development of dyskinesias and other motor complications greatly limits the use of levodopa therapy in Parkinson's disease (PD)...
- Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbancesDiederik E Tenback
Psychiatric Center Altrecht, Den Dolder, The Netherlands
Neuropsychopharmacology 31:1832-7. 2006..This may suggest a shared, pandopaminergic pathological mechanism associated with schizophrenia itself, rather than only a medication effect...
- Cerebral palsy in southern Sweden I. Prevalence and clinical featuresE Nordmark
Department of Physical Therapy, Lund University, Sweden
Acta Paediatr 90:1271-6. 2001..4 per 1,000. The distribution according to gestational age, birthweight and subdiagnoses was similar to that in earlier Swedish studies, except for a higher rate of dyskinetic syndromes in this study...
- Familial (idiopathic) paroxysmal dyskinesias: an updateK P Bhatia
Department of Clinical Neurology, Institute of Neurology, University College London, United Kingdom
Semin Neurol 21:69-74. 2001..The paroxysmal dyskinesias share features and therefore may have the same pathophysiological mechanisms as other episodic neurological ..
- Treatments for Parkinson disease--past achievements and current clinical needsWerner Poewe
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Neurology 72:S65-73. 2009..levodopa-related motor complications are only partially effective, rarely abolishing motor fluctuations or dyskinesias. Best results are currently achieved with invasive strategies via subcutaneous (s.c...
- Dyskinesias following neural transplantation in Parkinson's diseasePeter Hagell
Section of Restorative Neurology, Wallenberg Neuroscience Center, SE 221 84 Lund, Sweden
Nat Neurosci 5:627-8. 2002Severe dyskinesias during the 'off' phases (periods of increased Parkinson's disease (PD) disability) have been observed following intrastriatal transplantation of human embryonic mesencephalic tissue...
- Factors associated with the development of motor fluctuations and dyskinesias in Parkinson diseaseRobert A Hauser
Department of Neurology, University of South Florida, Tampa, FL 33606, USA
Arch Neurol 63:1756-60. 2006Motor fluctuations and dyskinesias can cause disability and reduce quality of life for patients with Parkinson disease (PD).
- Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadineM Merello
Movement Disorders Section, Raul Carrera Institute for Neurological Research, FLENI, Montaneses 2325, Capital Federal, C1428AQK, Buenos Aires, Argentina
J Neurol Neurosurg Psychiatry 77:172-4. 2006b>Dyskinesias are a transient but severe complication of subthalamotomy in some patients.
- Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesiasFrederic Calon
Molecular Endocrinology and Oncology Research Center, Laval University Medical Center CHUL and Faculty of Pharmacy, Laval University, Ste Foy, Quebec, Canada
Brain 127:1075-84. 2004..Fourteen levodopa-treated Parkinson's disease patients, of which seven developed dyskinesias and seven did not, were compared with nine controls...
- Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesiasKenneth A Follett
Department of Neurosurgery, University of Iowa Hospitals and Clinics, and Iowa City Veterans Administration Medical Center, Iowa City, Iowa 52242, USA
Neurosurg Focus 17:E3. 2004Deep brain stimulation (DBS) can relieve dyskinesias effectively and safely. This modality is applied most commonly in the treatment of dyskinesias associated with levodopa therapy for Parkinson disease...
- Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesiasStefano Zoccolella
Department of Neurological Sciences, University of Bari, Bari, Italy
Clin Chem Lab Med 44:863-6. 2006..for the development of long-term L-dopa motor complications (such as wearing off and on-off phenomena, and dyskinesias)...
- Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's diseaseDag Nyholm
Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185, Uppsala, Sweden
Expert Rev Neurother 6:1403-11. 2006..Motor fluctuations and dyskinesias develop with time as a consequence and can become disabling...
- Duration of amantadine benefit on dyskinesia of severe Parkinson's diseaseA Thomas
Neurophysiopathology, Movement Disorders Centre, Department of Oncology and Neuroscience, Universita G D Annunzio, Chieti Pescara, Pescara, Italy
J Neurol Neurosurg Psychiatry 75:141-3. 2004..A double-blind study programmed over 12 months was designed to assess the duration of the antidyskinetic effect of amantadine on levodopa induced dyskinesia...
- Management for motor and non-motor complications in late Parkinson's diseaseDaniel K Y Chan
University of New South Wales, and Department of Aged Care and Rehabilitation, Bankstown Lidcombe Hospital, Australia
Geriatrics 63:22-7. 2008..The practical evidence-based management of motor and non-motor complications in late PD is discussed...
- Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesiaMark Stacy
Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
Clin Neuropharmacol 31:120-5. 2008..In patients with advanced Parkinson disease, it is often not possible to induce periods of good mobility without dyskinesia...
- [Motor symptoms in Parkinson disease]Jan Petter Larsen
Nevrologisk avdeling, Stavanger universitetssjukehus, 4068 Stavanger
Tidsskr Nor Laegeforen 128:2068-71. 2008..This paper describes how to diagnose Parkinson's disease and the various motor complications and gives recommendations on how to treat the symptoms in these patients...
- The first evaluation of brain shift during functional neurosurgery by deformation field analysisD Winkler
Department of Neurosurgery, University of Leipzig, Leipzig, Germany
J Neurol Neurosurg Psychiatry 76:1161-3. 2005..This case report shows the need to reduce risk factors for intraoperative brain movement and demonstrates the ability of deformation field analysis to quantify this complication...
- The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 yearsMariese A Hely
Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia
Mov Disord 23:837-44. 2008..The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine...
- Nighttime sleep problems and daytime sleepiness in Parkinson's diseaseDagmar Verbaan
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
Mov Disord 23:35-41. 2008..No strong relations were found between DS and demographic or clinical variables. The strong relation between NSP and depressive symptoms in PD calls for future studies to explore the nature of this relation...
- Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's diseaseK Yamada
Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Acta Neurochir (Wien) 150:15-22; discussion 22. 2008..We retrospectively investigated the effects of bilateral STN stimulation on the axial signs unresponsive to levodopa in Japanese patients with PD...
- Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleusKaren Østergaard
Department of Neurology, Aarhus University Hospital, Nørrebrogade, Aarhus C, Denmark
Mov Disord 21:624-31. 2006..Five patients developed dementia. Severe adverse events were not observed...
- Paradoxical kinesia at warIlana Schlesinger
Department of Neurology, Rambam Health Care Campus, Haifa, Israel
Mov Disord 22:2394-7. 2007..002), and depression (P < 0.01) as compared with their performance before the war. Paradoxical kinesia is uncommon, even in the face of danger. Visual, but not auditory, triggers appear to be needed to prompt its occurrence...
- Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson diseaseRobert A Hauser
Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
Clin Neuropharmacol 29:322-30. 2006....
- Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmissionPaolo Gubellini
Equipe IC2N, Institut de Biologie du Developpement de Marseille Luminy IBDML, UMR6216, 31, Chemin Joseph Aiguier CNRS Université de la Méditerranée, 13402 Marseille, Cedex 20, France
Eur J Neurosci 24:1802-14. 2006..The interaction between these two treatments provides further evidence that striatal glutamatergic hyperactivity is a pathophysiological correlate of akinesia rather than LID...
- Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's diseaseSun J Chung
Center for Parkinsonism and Other Movement Disorders, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Eur Neurol 56:127-32. 2006..No patient exhibited permanent side effects. These findings indicate that unilateral STN-DBS may be a reasonable surgical procedure for selected PD patients who have markedly asymmetric parkinsonism...
- Efficacy and safety of simultaneous bilateral pallidotomy in advanced Parkinson's diseaseSun J Chung
Department of Neurology, Center for Parkinsonism and Other Movement Disorders, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Eur Neurol 56:113-8. 2006....
- Perceptual factors contribute to akinesia in Parkinson's diseaseB Ballanger
Laboratoire Performance Motricité et Cognition, University of Poitiers, Poitiers, France
Exp Brain Res 179:245-53. 2007..This suggests that the high-level perceptual deficits observed in the present study do not have a dopaminergic origin...
- [Medical treatment of Parkinson's disease]D Waldvogel
Neurologische Praxis Luzern, Hirslanden Klinik St Anna, Luzern
Ther Umsch 64:15-20. 2007..However, proper treatment of PD has to address the non-motor symptoms and the complications of therapy as well...
- High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's diseaseAbid Oueslati
Developmental Biology Institute of Marseille Luminy, Unite Mixte de Recherche 6216, Centre National de la Recherche Scientifique Université de la Méditerranée, 13402 Marseille Cedex 20, France
J Neurosci 27:2377-86. 2007..Only animals showing severe L-DOPA-induced dyskinesias (LIDs) were included, and STN-HFS was applied for 5 d at an intensity efficient for alleviating akinesia ..
- Prevalence and treatment strategies of dyskinesia in patients with Parkinson's diseaseT Muller
Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
J Neural Transm 114:1023-6. 2007..Treatment of dyskinesia was looked upon as not satisfactory, fractionating of levodopa dose was used as first choice therapeutic option of dyskinesia...
- OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's diseaseMatthew A Brodsky
Department of Neurology, Oregon Health and Science University, and Parkinson s Disease Research, Education and Clinical Care Center, Portland VA Medical Center, Portland, Oregon, USA
Mov Disord 21:1487-90. 2006A 61-year-old man with Parkinson's disease (PD), motor fluctuations, and dyskinesias underwent bilateral implantation of deep brain stimulation (DBS) electrodes in the subthalamic nucleus (STN)...
- Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcomeAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 22:1145-9. 2007..05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients...
- Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's diseaseAndrzej Dekundy
Preclinical R and D, Merz Pharmaceuticals GmbH, Eckenheimer Landstr 100, 60318 Frankfurt am Main, Germany
Brain Res Bull 69:318-26. 2006..However, mGluR5 antagonists may prove useful for the symptomatic treatment of L-DOPA-induced dyskinesia...
- New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonistsAnnalisa Pinna
CNR Institute of Neuroscience Cagliari section, Italy
Life Sci 77:3259-67. 2005..have shown that a low dose of L-DOPA plus KW-6002 produced symptomatic relief no different from that produced by an optimal dose of L-DOPA alone, whereas dyskinesias were reduced rendering this class of compounds particularly attractive.
- Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleusRoland Wenzelburger
Department of Neurology, Christian Albrechts University, Kiel, Germany
Ann Neurol 52:240-3. 2002Deep-brain stimulation of the subthalamic nucleus appears to reduce levodopa-induced dyskinesias, but whether this effect is caused by the reduction of the total levodopa ingestion or represents a direct effect on the motor system is ..
- Motor complications in Parkinson disease: a prospective follow-up studyPedrox J García Ruiz
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Clin Neuropharmacol 27:49-52. 2004..3 points; year 3, 22.6 points; year 4, 24.9 points; year 5, 29.5 points). Motor fluctuations, dyskinesias, and freezing also increased after year 3 from 10%, 16%, and 8% respectively to 35%, 32%, and 27% at year 5...
- [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)]J Vaamonde
, Complejo Hospitalario de Ciudad Real
Neurologia 16:81-4. 2001..with Parkinson's disease (PD) treated chronically with levodopa, with daily severe motor fluctuations and dyskinesias. PATIENTS AND METHODS: We introduced entacapone (200 mg added to every dose of levodopa) to 8 parkinsonian ..
- Dopaminergic hypersensitivity in patients with Parkinson disease and migraineEsther Cubo
Sanatorio del Rosario, Clinica de la Zarzuela, Department of Neurology, Madrid, Spain
Clin Neuropharmacol 27:30-2. 2004..These data support the hypothesis that migraine may be associated with dopaminergic hypersensitivity...
- Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)N Stefanova
Department of Neurology, University Hospital of Innsbruck, Innsbruck, Austria
Neurobiol Dis 15:630-9. 2004..Striatal FosB/Delta FosB up-regulation in SND and PD rats correlated with the severity of L-DOPA-induced dyskinesias. Pulsatile L-DOPA administration in the double lesion SND rat model replicates salient features of the human ..
- Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approachFabio Blandini
Laboratory of Functional Neurochemistry, Neurological Institute C Mondino, Pavia, Italy
Exp Neurol 184:556-60. 2003
- Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's diseaseJohn G Nutt
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201 3098, USA
Exp Neurol 184:9-13. 2003
- Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's diseaseFabrizio Stocchi
Institute of Neurology and Neuromed, University La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
Brain 125:2058-66. 2002..This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia...
- Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?P Martinelli
Dipartimento di Scienze Neurologiche, Universita di Bologna, Bologna, Italy
Neurol Sci 24:192-3. 2003..the potential sex-related differences in levodopa pharmacokinetics and their relation with the presence of dyskinesias in a group of 115 patients (67 men, 49 women) with Parkinson's disease...
- Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movementsRoland Wenzelburger
Department of Neurology, Christian Albrechts Universitat Kiel, Kiel, Germany
Mov Disord 18:1162-9. 2003..Other akinesia items and the time for build-up of lifting force were equally improved in both conditions. This suggests that routine STN-DBS might not be equally effective on all aspects of fine motor functions...
- Principles of Therapy in Cerebellar Disease: Explorations in Ion Channel MutantsJOHN SAMUEL STAHL; Fiscal Year: 2013....
- Autoimmunity Against Novel Antigens in Neuropsychiatric DysfunctionJosep O Dalmau; Fiscal Year: 2013....
- Synaptic autoimmunity in disorders of memory, behavior, cognition and psychosisJosep Dalmau; Fiscal Year: 2010....
- A Phase II Trial of Levodopa in Angelman Syndrome Wen Hann Tan; Fiscal Year: 2013....
- Molecular Mechanisms Controlling Formation of Basal Ganglia CircuitryKENNETH J CAMPBELL; Fiscal Year: 2013....
- CRCNS: Propagation of beta oscillations in cortico-basal ganglia-thalamic loopMichelle M McCarthy; Fiscal Year: 2013..its efficacy is limited by the "wearing off" phenomenon and its potential to engender potentially disabling dyskinesias ...
- Characterization of Striatal Nitric Oxide SignalingAnthony West; Fiscal Year: 2009..Parkinson's disease (PD), but lose effectiveness with time and produce debilitating side effects such as dyskinesias. Recent studies suggest that alterations in striatal cyclic nucleotide homeostasis are critically involved in ..
- Roles of Gsh1 &Gsh2 in Telencephalic NeurogenesisKENNETH J CAMPBELL; Fiscal Year: 2012..abstract_text> ..
- Prevalence of FMRI Expansions in Movement DisordersDeborah A Hall; Fiscal Year: 2010..These illnesses represent an important public health problem as they cause morbidity and mortality in our aging population. ..
- ROLE OF DOPAMINE RECEPTORS IN PRIMARY FOCAL DYSTONIASMorvarid Karimi; Fiscal Year: 2013..Selective ligands for D2 R, D3 R and D1-like receptors could be used to investigate the pathophysiology of dyskinesias in PD given their likely role in development of this disabling side effect of PD therapy...
- Reducing Dyskinesia in Parkinson Disease with Omega-3 Fatty AcidsKATHRYN ANNE CHUNG; Fiscal Year: 2012DESCRIPTION (provided by applicant): Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most patients with Parkinson disease(PD) as a consequence of chronic use of the most effective symptomatic drug, ..
- Paraneoplastic Disorders of the CNS: Autoantigen ProfilingJosep O Dalmau; Fiscal Year: 2013..dementia with CSF inflammatory/autoimmune features, 2) opsoclonus-myoclonus-ataxia, 3) acute encephalitis with dyskinesias, and 4) encephalitis with refractory-relapsing seizures...
- Role of Endocannabinoids in Levodopa-Induced DyskinesiasAndrea Giuffrida; Fiscal Year: 2012..therapy - the gold standard in Parkinson's disease (PD) treatment - causes disabling motor complications (dyskinesias) that are largely resistant to available drugs...
- L-DOPA-induced dyskinesias and dysregulation of striatopallidal neuronsSTEVEN MICHAEL GRAVES; Fiscal Year: 2013..receptors exclusively activated by designer drugs (DREADDs) in Parkinson's disease (PD) and L-DOPA-induced dyskinesias (LIDs)...
- Kinesia-D: Ambulatory PD Dyskinesia Monitor for Drug Therapy TitrationTHOMAS OLIVER MERA; Fiscal Year: 2013..testing and/or the patient's subjective assessment of and ability to distinguish between PD tremor, dyskinesias, and voluntary movements throughout the day...
- A2AR/mGluR5 Antagonist Combination Antiparkinsonian Therapy in MPTP MonkeysJames Bogenpohl; Fiscal Year: 2010..Current long term dopamine replacement therapies result in dyskinesias and other debilitating side effects...
- Nigrostriatal Tract ReconstructionJOHN RICHARD SLADEK; Fiscal Year: 2010..In some clinical trials patients who initially showed some level of motor improvement eventually showed dyskinesias that are postulated to be due to uncontrolled or excessive release of dopamine by the grafts...
- Aberrant Synaptic Plasticity: Impact on Dopamine Graft OutcomeKATHY STEECE STEECE-COLLIER; Fiscal Year: 2011..As the disease progresses, therapeutic benefit can wane, and significant side effects such as dyskinesias can impose additional limitations...
- Aging and Parkinson's Disease: Models of Therapeutics and Neurologic ComorbidityTimothy J Collier; Fiscal Year: 2013..with development of adverse consequences of disease and treatment (such as depression and therapy-induced dyskinesias) and mechanisms associated with translational therapeutics (such as subthalamic nucleus DBS and progenitor ceU ..
- Gene expression regulatory circuitry and microRNAs in midbrain dopamine neuronsAsa Abeliovich; Fiscal Year: 2013..with midbrain dopamine neurons (mDNs), including Parkinson's disease (PD), schizophrenia, autism, dyskinesias, and drug addiction...
- Ischemic Spasticity: Modulation by GAD65 Gene DeliveryMartin Marsala; Fiscal Year: 2010..intrastriatal injections of adeno-associated virus encoding GAD65 gene is effective in suppressing parkinsonian dyskinesias and is associated with an increase in local GABA release...
- [18F]FPEB Studies of the mGluR5 Receptor and Methamphetamine AbuseROBERT MICHAEL KESSLER; Fiscal Year: 2013..Huntington's disease, depression, and anxiety disorders as well as playing an important role in motor dyskinesias in Parkinsons disease...
- Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's DisNurulain T Zaveri; Fiscal Year: 2010..Our proposal investigates a new, relatively unexplored target for PD therapy and L-Dopa induced dyskinesias, and proposes to develop novel drug candidates against this target, to validate this target as being suitable ..
- Frontal-Subcortical Development, Movement Abnormalities, and Risk for PsychosisVijay A Mittal; Fiscal Year: 2013..patterns of grey and white matter in the FSC system characterize prodromal populations and result in dyskinesias and/or Parkinsonisms) and if developmental abnormalities in this system and SMAs (a potential biomarker that ..
- Functional Brain Networks: A Novel Approach to Address Clinical Challenges in PDDavid Eidelberg; Fiscal Year: 2013..Project 1 addresses the serious clinical problem of levodopa-induced dyskinesias, which ultimately affect nearly all PD patients...
- Mechanisms of nicotine-mediated decrease in L-dopa induced-dyskinesiasMaryka Quik; Fiscal Year: 2013..DESCRIPTION (provided by applicant): Our overall aim is to elucidate the mechanisms that underlie L-dopa-induced dyskinesias (LIDs) and to develop anti-dyskinetic strategies, with a focus on the nicotinic cholinergic system...
- Kinesia-D: Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy TitTHOMAS OLIVER MERA; Fiscal Year: 2011..with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced choreatic dyskinesias, or irregular rapid involuntary movements, in Parkinson's disease (PD)...
- Manipulating Gene Expression in the Dyskinesias of Parkinson's DiseaseStella M Papa; Fiscal Year: 2013..of dopaminergic therapy in Parkinson's disease, namely the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to ..
- Validation of PPARgamma agonists as anti-dyskinetic drugsAlex Anthony Martinez; Fiscal Year: 2013..associated with disabling side effects consisting of uncontrolled involuntary movements known as L-DOPA-induced dyskinesias (LID)...
- Functional circuit disorders of sensory cortex in ASD and RTTGregory C Carlson; Fiscal Year: 2012..Symptoms can include stereotypic dyskinesias, autistic features, including language delay and regression, breathing abnormalities, and abnormal central EEG ..
- EMBRYONIC DOPAMINE CELL IMPLANTS FOR PARKINSONISMCurt Freed; Fiscal Year: 2005..Some of the transplanted patients develop dyskinesias (abnormal, excess movements) even off agonist therapy, starting typically more than one year after surgery...
- Cortical contributions to basal ganglia disordersPETER STRICK; Fiscal Year: 2006..These injections produce reversible dyskinesias, hyperactivity, attention deficits or stereotypes, depending upon the location of the injection site...
- Translational Foundation of Adenosine Antagonist Use for DyskinesiasMichael A Schwarzschild; Fiscal Year: 2010..Preclinical evidence that A2A antagonists reliably reduce motor disability without producing dyskinesias (motor complications of standard L-dopa therapy) in parkinsonian primates has led to encouraging initial ..
- Evaluating BMY-14802 as an anti-dyskinesia treatment in the 6-OHDA rat model of PMELANIE PAQUETTE; Fiscal Year: 2009..of people who take L-DOPA eventually develop debilitating side effects, abnormal involuntary movements called dyskinesias, which may affect the limbs, body, and or face...
- Focal Dopamine Indicated in Dyskinesias in MPTP MonkeysKrystof S Bankiewicz; Fiscal Year: 2010The broad aim of this proposal is to test the hypothesis that L-dopa-induced dyskinesias (LID) in Parkinson's disease (PD) arise at least in part from non-uniform dopaminergic denervation of the striatum, whereby islands of ..
- STUDIES IN ORAL PHARYNGEAL REFLEXESScott Chandler; Fiscal Year: 1993..The importance of jaow and tongue control in prosthodontics is becoming more evident. Dyskinesias involving the jaw and tongue are also manifest in tardive dyskinesia, senility, stroke and in comatose patients...
- ORAL PHARYNGEAL REFLEXESLouis Goldberg; Fiscal Year: 1992..The importance of jaow and tongue control in prosthodontics is becoming more evident. Dyskinesias involving the jaw and tongue are also manifest in tardive dyskinesia, senility, stroke and in comatose patients...
- PDRemote: Automated Telehealth Diagnostics for Remote Parkinson's MonitoringJoseph P Giuffrida; Fiscal Year: 2010..Major PD symptoms include tremor, bradykinesia, and rigidity. Additionally, dyskinesias or wild involuntary movements as a side effect of drug therapy can be a motor complication...
- STREP, HOST FACTORS, AUTOANTIBODIES & TOURETTE SYNDROMEHarvey Singer; Fiscal Year: 2000..children with TS and b) after intrastriatal injection of purified serum IgG from TS patients, rodents developed dyskinesias associated with antibody binding to striatal neurons...
- Functional Studies of Subtypes of Parkinson's DiseaseeXuemei Huang; Fiscal Year: 2007..PD (PDT) generally has better long-term motor outcome with fewer motor fluctuations, less levodopa-induced dyskinesias, a slower rate of progression, and fewer cognitive deficits when compared with akinetic-rigid-predominant PD (..
- HALOPERIDOL AND ATTENTIONAL LEARNING IN AUTISTIC CHILDREMagda Campbell; Fiscal Year: 1991..autistic children who require pharmacotherapy, are sought because of the high incidence of neuroleptic-related dyskinesias. (2) We also wish to continue our long-term prospective study of haloperidol in autistic children: to assess ..
- PET IN HYPERKINETIC DISORDERS--A MULTICENTER STUDYDavid Eidelberg; Fiscal Year: 2001..This approach may have great utility in evaluating new interventions for the treatment of the hyperkinetic movement disorders. ..
- TorsinA function and dystonia-related dysfunction in developing and mature CNSWilliam T Dauer; Fiscal Year: 2013....
- Advanced Technology and Tools for DBS Programming for Speech FunctionalityCraig van Horne; Fiscal Year: 2009..after DBS were noted, they were typically minimal and more variable than seen in akinesia, rigidity, and dyskinesias." This project's goal is to develop an inexpensive portable device and software tools that will ..
- GABA AGONIST THERAPY IN TARDIVE DYSKINESIACarol Tamminga; Fiscal Year: 1999..a therapeutic effect of clozapine in TD and now are seeking to understand whether clozapine improves dyskinesias in TD through diminishing these same neuroleptic-induced GABAergic changes in the substantia nigra pars ..
- DEEP BRAIN STIMULATION--COGNITION/MOTIVATION/MOOD IN PDMarjan Jahanshahi; Fiscal Year: 2005..of Parkinson's disease (PD), particularly improving akinesia and rigidity and reducing levodopa-induced dyskinesias. Neuropsychological investigations have shown that such beneficial effects of DBS on motor function are ..
- NEUROLEPTIC-INDUCED DYSKINESIAS AND DYSTONIASGaylord Ellison; Fiscal Year: 1992..to pursue this model, which we argue is presently the best viable rodent model of neuroleptic-induced oral dyskinesias, by studying how drugs which affect dopamine or cholinergic receptors, as well as other pharmacological agents, ..
- Levodopa Pharmokinetic Optimization by Metal CoordinationThomas Piccariello; Fiscal Year: 2009..often experience a need to maintain plasma drug levels within a narrowing therapeutic window in order to avoid dyskinesias, associated with high drug levels, and off periods that occur when levels are low...
- NEUROIMAGING OF HYPERKINETIC MOVEMENT DISORDERSMichael Hutchinson; Fiscal Year: 2001..Validation of this approach will mediate between existing theories of cortical-subcortical interactions, and may suggest possible surgical or pharmacological intervention in these disorders. ..
- GLUTAMATE IN PARKINSON'S DISEASEJ Greenamyre; Fiscal Year: 2003..3. Compare the development and severity of dyskinesias in de novo parkinsonian monkeys treated chronically with (1) levodopa alone, or (2) a combination of levodopa ..
- SIGNALING MECHANISMS IN DOPAMINE RECEPTOR SYNERGISMYuan Luo; Fiscal Year: 2007..the expression or progression of diverse neurological and psychiatric diseases, including Parkinson disease, dyskinesias, schizophrenia, drug addiction, and Tourette disorder...
- Levodopa dyskinesia and striatal neuroplasticityChristine Konradi; Fiscal Year: 2007..L-DOPA treatment are eventually afflicted with motor fluctuations and abnormal, involuntary movements known as dyskinesias. L-DOPA-induced dyskinesias can become more disabling than Parkinson's disease itself...
- NOVEL ANTIPSYCHOTICS AND STEREOTYPED MOVEMENT DISORDERKarl Newell; Fiscal Year: 2007..of adaptive, goaloriented actions? And (4) Are there differences between the short and long term effects of atypical antipsychotics on aberrant behavior, abnormal movements, and goal-oriented motor task performance? ..
- Adapative Wireless Computer Mouse for Movement DisordersJOSEPH GIUFFRIDA; Fiscal Year: 2006..Major symptoms of PD include tremor, dyskinesias, bradykinesia, and rigidity. ET produces tremors that affect motor function...
- Deep Brain Stimulation Using Microactuated MicroprobesJit Muthuswamy; Fiscal Year: 2006..It is also a promising therapy for epilepsy, dyskinesias, obsessive-compulsive and anxiety disorder...
- DEEP BRAIN STIMULATION FOR PARKINSONS DISEASEJERROLD VITEK; Fiscal Year: 2005..of patients experience worsening of their parkinsonism and develop incapacitating motor fluctuations and dyskinesias. To deal with this, attention has been directed to surgical procedures, especially ablative therapies, e.g...
- Wireless Movement Disorder MonitorJOSEPH GIUFFRIDA; Fiscal Year: 2009..Three major PD symptoms that affect quality of life include tremor, bradykinesia, and dyskinesias. These symptoms are often responsible for functional disability and social embarrassment...
- Continuous Dopaminergic Stimulation: Parkinson's DiseaseThomas Smith; Fiscal Year: 2005..as to adverse effects of treatment of PD and may also contribute to progression of motor side effects such as dyskinesias. Continuous dopaminergic stimulation has therefore been considered an important therapeutic goal...
- ALTERED SEROTONIN SIGNAL TRANSDUCTION IN DYSKINESIASWilliam Wolf; Fiscal Year: 2000..term objective of this research is to determine the neurochemical mechanisms underlying antipsychotic-induced dyskinesias. Antipsychotics, such as haloperidol, are widely used in the treatment of schizophrenia and in agitated elderly ..
- ROLE OF VENTROLATERAL THALAMUS IN CEREBELLAR TREMORJERROLD VITEK; Fiscal Year: 1992..These studies may lead to the development of new therapeutic strategies for the treatment of movement disorders...
- ABNORMAL MOVEMENTS AND PHARMACOLOGY OF THE FOREBRAINS Snodgrass; Fiscal Year: 1980..Since this recovery is reversible with PCPA (a blocker of serotonin synthesis) it seems to depend upon restoration of 5-HT neuronal function, most likely in the substantia nigra...
- Molecular Basis of D1 and D2 PrimingAlexia Pollack; Fiscal Year: 2003Response fluctuations and dyskinesias are often associated with chronic dopamine-replacement therapy for Parkinson's disease (PD). It is these 'side-effects' that severely limit the long-term usefulness of this therapy...